IM-862 in Treating Patients With Recurrent Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 28, 1999

Primary Completion Date

July 31, 2000

Study Completion Date

August 31, 2001

Conditions
Ovarian Cancer
Interventions
DRUG

oglufanide disodium

Trial Locations (1)

90033-0800

USC/Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT00003773 - IM-862 in Treating Patients With Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter